Welcome to our dedicated page for Biohaven news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven stock.
Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company whose news flow centers on progress across its immunology, obesity, neuroscience and oncology pipelines. Company updates frequently cover clinical trial readouts, regulatory interactions, financing events and scientific presentations that shape the outlook for its drug development platforms.
Investors and followers of BHVN news can expect detailed announcements on Biohaven’s Kv7 ion channel modulation programs, including opakalim in refractory focal epilepsy and major depressive disorder, as well as updates on the MoDE™ and TRAP™ extracellular degrader platforms targeting immune-mediated diseases such as IgA nephropathy and Graves’ disease. News releases also highlight the advancement of taldefgrobep alfa, a myostatin-activin pathway inhibitor in obesity and SMA, and BHV-8000, a brain-penetrant TYK2/JAK1 inhibitor in pivotal studies for early Parkinson’s disease.
Biohaven’s oncology news often focuses on early clinical data from its next-generation antibody-drug conjugates, including BHV-1510, a Trop2-directed ADC, and BHV-1530, an FGFR3-directed ADC, with reports of tumor responses, safety profiles and combination strategies with checkpoint inhibitors. Additional coverage includes regulatory milestones such as the FDA Complete Response Letter for VYGLXIA (troriluzole) in spinocerebellar ataxia and the company’s stated plans for further regulatory dialogue.
Capital markets and corporate updates—such as public offerings of common shares, at-the-market transactions, portfolio reprioritization and cost-optimization measures—also feature prominently in BHVN news. Readers who monitor this stream gain insight into Biohaven’s evolving clinical strategy, key upcoming milestones and how the company allocates resources across its late-stage programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Biohaven Ltd. (NYSE: BHVN) announced the appointment of Nick Kozauer, M.D. as Senior Vice President for Clinical Development and Regulatory Strategy. Dr. Kozauer, formerly at the FDA, directed the Division of Neurology 2, overseeing drug applications for various neurological conditions. His extensive experience includes the approval of over 15 drugs, enhancing Biohaven's potential to advance its pipeline targeting diseases with significant unmet needs. CEO Vlad Coric emphasized that Dr. Kozauer's expertise will strengthen Biohaven’s ability to innovate in neuroscience therapeutics. Biohaven's portfolio includes therapies for rare and debilitating neurological disorders, leveraging advanced drug development capabilities. This executive addition signifies Biohaven's commitment to enhancing its operational strength and advancing treatments for patients.